...excellence
and passion

A team of >300 employees
in >30 countries

 

30% R&D

EXECUTIVE TEAM

 

The greatest minds in biotechnology and machine learning are at work at SOPHiA GENETICS, continuously honing our algorithms, offers and services for the benefit of clinical researchers worldwide. About 80% of our organization holds a PhD, ranging anywhere from Cell Biology to Computer Science. This international and dedicated team is the key to our current success and is the promise of an even greater future ahead for us and the world of Data-Driven Medicine.

Jurgi Camblong

Founder and CEO

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Dr. Camblong has been a member of the Advisory Council on Digital Transformation to the Swiss Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.  

Bram Goorden

SVP - Chief Operating Officer

Bram Goorden is an accomplished commercial executive with 20 years of experience in life sciences. He joined SOPHiA GENETICS in 2020 as Chief Commercial Officer and also serves as the Head of North America based in Boston, Massachusetts. He comes from Foundation Medicine Inc. (Cambridge, MA), where he held the role of VP International Business and Partnering in charge of expanding the global footprint of the company to become a leader in precision medicine. Prior to that he was General Manager, Head of Therapeutics with Prometheus Labs (San Diego, CA), a Nestle Health Science company, and has held global roles of increasing responsibility in strategic and operations management with Eli Lilly and UCB Pharma. He is passionate about the role of data in improving patient care and he has had the opportunity to successfully launch novel solutions in different areas of healthcare. Bram serves on the boards of several companies and associations and is a former member of patient advocacy and philanthropic healthcare organizations.
He has a BA from the University of Bologna - Italy, an MSc from the University of Antwerp – Belgium in Commercial Engineering. He has followed executive educations at the Kellogg School of Management and Harvard Business School.

Lara Hashimoto

SVP - Chief Business Officer

Growing up in Canada, Lara developed an early interest in understanding the role of genetics in common diseases. This took her from studying genetics of Multiple Sclerosis at the University of Western Ontario to joining the Wellcome Trust Centre for Human Genetics at the University of Oxford, UK.
Lara joined SOPHiA GENETICS in 2020, but first joined industry 20 years ago as a Scientist at Roche Pharma based in Basel, Switzerland. She has held several positions spanning Pharma clinical drug development, business analytics and strategic marketing in the global organization as well as sales and operational marketing positions in the Canadian affiliate.
In 2009, Lara moved to Roche Molecular Diagnostics in California as the Lifecycle Leader responsible for the Genomics and Oncology IVD product portfolio and pipeline, launching several companion diagnostics globally. Lara then became the General Manager of Roche Diagnostics New Zealand Ltd where she grew sales above market for 4 consecutive years. Returning to the Bay Area, Lara then joined the newly formed Roche Sequencing Solutions team where she was the VP responsible for Non-Invasive Prenatal Testing and the Nanopore Sequencer before being appointed Chief Commercial Officer.

Philippe Menu

SVP - Chief Medical Officer

Dr. Philippe Menu (MD-PhD, MBA) brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the biopharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases. Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in Life Sciences from the Open University Business School.

Ross Muken

SVP - Chief Financial Officer

Ross Muken joined SOPHiA GENETICS in February 2021. He was most recently the CFO and COO of Click Therapeutics. Before joining Click, he was Partner, Senior Managing Director and Head of the Healthcare Services & Technology Research Team at Evercore ISI where he covered more than 50 companies across the Healthcare Technology & Distribution, Life Science Tools & Diagnostics, Managed Care & Facilities and Medical Supplies & Devices sub-sectors. Prior to joining Evercore ISI, Mr. Muken served as a Managing Director at Deutsche Bank Securities and spent time in the Equity Research division of Thomas Weisel Partners. He began his career as an M&A Investment Banker at Bank of America Securities after earning his B.S. in Business Administration, magna cum laude, at Boston University.

Kevin Puylaert

VP - Business Development

Kevin Puylaert is SOPHiA’s VP Business Development. He leads global efforts to expand the company's reach through strategic partnerships and acquisitions. His commitment and entrepreneurial spirit have been pivotal in accelerating the adoption of SOPHiA around the world: after successfully leading the company’s business development activities outside of Europe, Kevin was appointed General Manager of North America. During his time there, Kevin kickstarted the North American team and developments, setting up the Boston office and launching the company on the US market. Before joining the company, Kevin was a lead Strategy & Development Project Manager at the Clinique Universitaire Saint-Luc in Belgium. He completed his Masters in Science from the Louvain School of Management after a Bachelor in Business Engineering at the University of Leuven.

Manuela Valente

SVP - Chief People Officer  

Manuela Da Silva Valente is a seasoned Human Resources Executive with over 20 years experience working in international companies. Manuela has joined SOPHiA GENETICS in January 2019 from IQVIA (formerly Quintiles and IMS Health Inc.), a Human Data Science company, where she held a number of senior Human Resources roles with most recently the position of Global Senior Human Resources Director. Prior to this, she worked for several years at Outcome Sciences, where she successfully established the European operations and led the organization through the acquisition by Quintiles, a Global Clinical Research Organization.
Manuela obtained a Bachelor Degree in Business Administration from the Business Management School of Zurich and a Management & Human Resources Diploma from CEFCO Lausanne.
Used to work in fast-pacing companies, Manuela has extensive experience in aligning people strategies with business objectives and driving significant organizational and cultural changes, by focusing on talent development and employee engagement.

Daan Van Well

SVP - General Counsel  

Daan van Well, LL.M, MBA, has more than 20 years of experience as a lawyer in top-tier private practice, in-house and consulting roles, and has extensive experience in legal, governance and compliance matters. Prior to joining SOPHiA GENETICS in June 2019, he was the Head of Legal at PwC in Geneva, Switzerland where he supported a large variety of healthcare and other clients with company mergers and acquisitions, business development, governance and compliance matters. Before that, after having held several in-house roles, Daan served as Corporate Secretary for international food retailer Ahold (currently Ahold-Delhaize), listed at the New York Stock Exchange and at AEX Euronext Amsterdam, where he oversaw all corporate activities, corporate finance and investor relations work. He started his career as a lawyer at international law firm Loyens & Loeff in Rotterdam, The Netherlands. Daan holds an LL.M in Dutch civil law from Utrecht University and an Executive MBA in Management and Corporate Finance from HEC Lausanne. In parallel to his legal career, Daan has co-founded low/no-alcohol craft beer company ABLOC. Daan is a vivid cycling enthusiast and loves to go the extra mile.

Zhenyu Xu

SVP - Chief Scientific Officer  

Dr. Zhenyu Xu is a genome scientist with a background in molecular and computational biology. He holds a Master’s degree from Cambridge University in computational biology, and obtained his PhD at the European Molecular Biology Laboratory (EMBL) where he focused on the transcriptome landscape of yeast. His PhD work systematically characterized the non-coding transcripts in yeast which lead to the unveiling that in a majority of cases, transcriptions are bidirectional. Zenyu is among the most experienced bioinformaticians worldwide in clinical NGS data analysis. He joined SOPHiA GENETICS in 2012 and is the leader of the technology team who developed SOPHiA – the universal technology for Data-Driven Medicine. The AI powered SOPHiA Platform, an advanced SaaS analytics platform for clinical genomics, is recognized and widely used in more than a thousand heathcare institutions across the world.

Sergei Yakneen

SVP - Chief Technology Officer  

Dr. Sergei Yakneen is an accomplished leader, technologist, and scientific researcher who brings a wealth of experience in financial technology, e-commerce, and cancer research. He joined SOPHiA GENETICS in September of 2019 after most recently working at the European Molecular Biology Laboratory in Heidelberg, Germany. He graduated from the University of Toronto with a degree in Computer Science and Mathematics and completed his PhD in Genomics and Computer Science at Heidelberg University. Over the past 15 years he’s led the Product Development and Professional Services groups of fin-tech startups, and launched Amazon.com’s first Software Engineering organization in the Toronto area. He led the technical working group of the world’s largest international cancer genome analysis project, the Pan Cancer Analysis of Whole Genomes, and devised new methods for analysis of genomic data at scale. Since 2013 Sergei has been focused on bringing the power of large-scale distributed computing to bear down on some of the hardest problems in cancer research.

BOARD OF DIRECTORS

Troy Cox

Chairman of the Board

Troy Cox is a pioneer in the precision medicine revolution. Former CEO of Foundation Medicine (FMI) - acquired by Roche in 2018 - Troy is today making a difference in patient’s lives by serving on corporate boards of innovative companies in the Biopharma, Diagnostic, and Tech industries. He is also committing his support to patient-focused non-profit organizations. In June 2019, Troy joined SOPHiA GENETICS’ Board of Directors to help the organization further advance Data-Driven Medicine. Prior to Foundation Medicine, Troy served as Senior Vice President and Officer at Genentech where he led US BioOncology for a period of unprecedented growth, participating in the launch of nearly half of the products from the world’s oncology leader. Other notable experiences include UCB, Sanofi-Aventis and Schering-Plough. Troy’s expertise spans across strategy, general management, commercial, and R&D. His pharmaceutical career began as a Sales Representative after earning his MBA at the University of Missouri. He also received a BBA in Finance from the University of Kentucky.

Jurgi Camblong

Founder and CEO

Dr. Jurgi Camblong is a visionary entrepreneur who is pioneering the Data-Driven Medicine movement around the world. He is a Molecular Biologist (published in Cell, Science & Nature), has a PhD in Life Sciences from the University of Geneva, and an EMBA in Management of Technology from EPFL/HEC Lausanne. In 2011, he founded SOPHiA GENETICS with Dr. Pierre Hutter and Prof. Lars Steinmetz. He has since successfully led the development of the company, listed among the 50 Smartest Companies by the MIT Technology Review. Dr. Camblong has been a member of the Advisory Council on Digital Transformation to the Swiss Government, and was personally recognized by EY as Emergent Entrepreneur of the Year in 2017.  

Antoine Duchateau

Board Member

Antoine Duchateau is a successful entrepreneur. He started his career with IBM Belgium as software engineer and sales executive for the financial sector in Brussels, then in 1981 joined the British BIS Banking Systems Group (BIS) in London, a worldwide leader in core banking application software, as Managing Director for Europe, then Chief Operating Officer. In 1995 he founded Odyssey Financial Technologies (OFT), which became over the years, the worldwide leader in mid-front office application software for the private banking sector. Under his direction as CEO and Chairman the company revenue grew to over $70M with 600 employees. In 2010, he executed the sale of Odyssey to Temenos Group AG. Following the sale of OFT, Antoine Duchateau decided to help start up and small to medium size enterprises by bringing his expertise. He was appointed Chairman of the Board of SOPHiA GENETICS in spring 2013.

Kathy Hibbs

Board Member

Kathy Hibbs is an accomplished health care technology executive and active board member with over two decades of expertise in health care and genomics. Kathy is the Chief Legal and Regulatory Officer of 23andMe, where she leads its complex legal operations and regulatory affairs. She is globally recognized for her effectiveness, having successfully pioneered the first ever FDA clearance for over-the-counter genetic testing. Regularly recognized as one of the Bay Area’s most influential women by the both the San Francisco and Silicon Valley Business Journals, Kathy is ranked by Chambers as among the most influential General Counsels in US. She sits on the boards of Decipher Biosciences, Inc. and Cadex Genomics Inc. During her 15 years’ experience as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX) and Monogram Biosciences, Inc. (NASDAQ: MGRM), Kathy developed her passion for personalized medicine and the power of innovation to improve the lives of patients. Kathy graduated Summa Cum Laude from the University of California, Riverside and received her Juris Doctorate from Hastings College of the Law.  

Didier Hirsch

Board Member

Didier Hirsch is the former Senior Vice President and Chief Financial Officer of Agilent Technologies, Inc., a global leader in life sciences, diagnostics and applied chemical markets, a position that he held from 2010 to 2018. He joined Agilent in 1999 at its inception, holding multiple leadership roles in finance. Prior to joining Agilent, Didier Hirsch had been with Hewlett-Packard Company since 1989, serving in leadership roles in finance and administration in EMEA and Asia Pacific. Previously, he held finance positions at Valeo Inc., Gemplus S.C.A., SGS-Thomson Microelectronics, I.B.H. Holding S.A., Bendix Corporation and Ford Motor Company. Didier Hirsch serves on the board of directors of Knowles Corporation and Logitech International S.A. He is the chair of the Audit Committee at both companies and serves on their Nominating Committee. Didier Hirsch holds a master's degree in computer science from Toulouse University in France and a master's degree in industrial administration from Purdue University in the U.S.

Dominique Mégret

Board Member

Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit. Previously, Dominique Mégret was a tech entrepreneur in the United Kingdom, a strategy consultant in the European telecom industry and country manager for an IT company in Germany. He holds an MBA from Insead.

Vincent Ossipow

Board Member

Dr. Vincent Ossipow, CFA, is Partner at Omega Funds and brings 22 years of healthcare investment experience in public and private companies. Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for Private Equity; and prior to it with Pictet Bank, where he co-managed the Pictet Biotech Fund. Vincent also has an extensive board member experience, as he has served on the board of directors of a dozen public and private companies over the last decade, such as LifeSpan, Bioinvent (STO: BINV), and Immunic (NASDAQ: IMUX). As a research fellow at the University of Geneva from 2000 to 2006, he worked on the molecular basis of brain function where he obtained a Ph.D. in molecular biology. Vincent trained as a postdoctoral fellow (Hoffman-La-Roche and Human Frontier Science Program fellow) in Geneva and at the National Cancer Institute NCI in Bethesda, Maryland, and completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business in Washington, D.C.

Michael Schenck

Board Member

Michael Schenck has served as a member of SOPHiA GENETICS Board of Directors since December 2015. Michael has been an Investment Manager at Alychlo, the investment firm of Belgian healthcare entrepreneur Marc Coucke, since July 2015 and currently serves on the board of directors of Fagron (Euronext: FAGR) and several private companies. Previously, Michael worked as Investment Manager at Waterland Private Equity from 2008 to 2014. He started his career in corporate finance in France and holds master’s degrees in business and management from Erasmus University Rotterdam and HEC Paris.

Milton Silva-Craig

Board Member

Milton G. Silva-Craig is a successful leader who has demonstrated expertise in building inclusive, high performance teams that have grown and scaled businesses in various fields of provider healthcare IT, including medical imaging, revenue cycle management and clinical data management. He has been the Chief Executive Officer of Q-Centrix the past six years, leading the company through a successful sale from private equity firm Sterling Partners to TPG Growth in late 2018. Prior to Q-Centrix, he served as president of TransUnion’s healthcare business unit, where, he developed and executed a strategic business plan focused on repositioning and growing TransUnion in the healthcare marketplace, resulting in an eightfold increase. Prior to TransUnion, Milton served as the President and Chief Operating Officer at Emageon Inc., leading the company’s strategic direction and operations. He grew revenues from several hundred thousand dollars to more than $100 million, and eventually led Emageon through its initial public offering on NASDAQ in 2005 (NASDAQ:EMAG). He also held executive positions at General Electric Medical Systems. Silva-Craig earned a J.D. from the University of Wisconsin School of Law in Madison and obtained his M.B.A. and B.A. from the University of Wisconsin – Madison.  

James Wise

Board Member

James Wise is a partner at Balderton Capital, a $4B venture fund focussed on early and growth stage technology companies. James works with companies in fields ranging from biotech, health, manufacturing and productivity and has been an investor in companies acquired by Microsoft and Amazon. He holds board and advisory positions with 8 technology companies. Prior to Balderton, James helped launch one of the UK's first Social Impact Funds, and has worked for both the British Government and McKinsey & Company. He holds an MA Oxon from Oxford University.